Small team, high focus With 2-10 employees and a specialized focus on AI-enabled antimicrobial R&D, General Probiotics presents a strategic opportunity to engage via high-touch, collaboration-first sales approaches and potential co-development partnerships.

Early-stage funding Funding of 1.4M and revenue under 1M indicate a capital-efficient startup prioritizing strategic partnerships, grant-informed projects, and pilot programs that can be accelerated through low-risk, grant-aligned product engagements.

AI-enabled R&D The emphasis on an AI-enabled R&D program suggests potential for selling AI-augmented data services, computational biology tools, or platform collaborations that complement their probiotic discovery and development workflow.

NSF and USDA grants Grant provenance from NSF and USDA signals credibility and access to government-backed funding channels; explore co-funded pilot studies, contract research, and milestone-based collaborations aligned with public funding objectives.

Probiotic antimicrobial niche As a proposer of tailored probiotics to eliminate pathogens, there is a market angle for B2B partnerships with biotech, healthcare, and animal health players seeking targeted antimicrobial solutions and outcome-driven trials.